Mirror on RB patting himself on the back lol Thinks vcsy is his friend. Man is he ever in for a rude awakening . Stay tuned mirror boy. And I do mean boy. Chump.
Sentiment: Strong Buy
I've told already 1000s time since hygs were at 30 bucks to sell off all your shares.
Now it will drop below 10 in the month or 2 months but it drops and drops.
Hydrogenics tries to get taxpayer money
Tesla Motors got almost 880 million dollars in once.
Hydrogenics will never get any.
Only money to pay management 4.4 million dollars
Sentiment: Strong Sell
TB, you don.t have to go as far afield as AAPL.
NPSP was recently snapped up by Shire for $5.2B and yet to turn a profit.
SGEN traded off all ex US rights to Takeda during phase2 and their market cap is almost $4.3B and yet to turn a profit.
The big difference here is if you go back through their 10 year charts, try to find any prices as low as $1.20. You will not find it.SGEN price was around $10 going into phase2s. You don't see $1.20 going into phase3s very often. I would like to see another like this if anybody knows of one.
This is an incredible opportunity at $1.20 on the verge of a pivotal phase3 if you believe there is chance of success.
If you want the AAPL biotech equivalent, consider DNA(genentech). Broke through with a new technology after battling for credibility.They wanted to use bacteria to make drugs. The rest is history. Roche bought the 1/2 it didn't own for $46.8B in 2009. The bio did not reach its potential till Roche came on board with the resources to drive through the blockbusters. Prana probably has more chance of a blockbuster early on than DNA had considering the HD, AD and PD programs.
Sentiment: Strong Buy
Will make a few people miss out on the opportunity of a lifetime! !
Cramer totally left out the company selling 6.5 billion of assets and a current market value of just 4.5bill.
He is an I-D-I-O-T!
The company has a market cap of $4.5 billion here at 9 and is selling $6.5 billion of assets! !
Long term care has been solved!
Even still the sales of assets over market cap of the entire company! !
What were you thinking Jim??
Go back on and give a more complete analysis!
Here is the 2009 SGEN deal, note, before the deal, looks like it was shared with Millennium. Even before the phase 2 price SGEN was around $10. Very rare to see $1.20 at the stage Prana is at.
December 15, 2009 – Seattle Genetics, Inc. and Millennium: The Takeda announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeting CD30 that is in late-stage clinical trials for the treatment of relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
Data from a pivotal phase II trial of brentuximab vedotin in relapsed or refractory HL, which is fully enrolled, are expected in the second half of 2010. The trial is being conducted under a special protocol assessment with the U.S. Food and Drug Administration (FDA) and is designed to provide the basis for regulatory submissions in the United States and Europe in 2011.
Under the collaboration, Seattle Genetics will receive an upfront payment of $60 million and retains full commercialization rights for brentuximab vedotin in the United States and Canada. The Takeda Group will have exclusive rights to commercialize the product candidate in all countries other than the United States and Canada. Seattle Genetics is entitled to receive progress- and sales-dependent milestone payments in addition to tiered double-digit royalties based on net sales of brentuximab vedotin within the Takeda Group’s licensed territories. Milestone payments to Seattle Genetics could total more than $230 million. Seattle Genetics and the Takeda Group will jointly fund worldwide development costs on a 50:50 basis. Development funding by the Takeda Group over the first three years of the collaboration is expected to be at least $75 million. In Japan, the Takeda Group will be solely responsible for development costs.
Sentiment: Strong Buy
By John Goreham G+ 2015-04-30 14:49 - google it and you will understand that Musk is wrong about hydrogen fuel cell electric vehicle and it is understandalbe that he denies the competitiveness of hydrogen fuel cell electric vehicle as he is stuck with batteries for his EVs.
A study continuation does NOT equal study failure! Most Phase 3 trials don't stop at the interim phases and typically go through full study completion before it's known if the drug is effective or not. Since the results of the Phase 2 study were so exciting, I think the market expectation is that the Phase 3 will stop early (and it very well may), but if it doesn't the world will not come tumbling down... Sure, we'll take a hit on the pps, but it will stabilize and we'll wait until the 444th event occurs. With that said, I still feel there is good chance the study will stop, but if it doesn't I'm not going to panic and sell..
schroe - IV vs oral treatments. Do they really have to ponder over which method will be more be efficacious? It doesn't seem too difficult to reach the right conclusion.
Bristol Myers Squibb and Eli Lilly are working with aldoxorubicin
So just how bad is the oil field employment down there? My nephew was laid off from his fracking job. From what he sounded with no time frame of when he would be back to work. I guess I am looking at this from a employment stand point across the US also. Supposedly down in the major oil fields you have major cities springing up like gold rush days.
Other than oil, looking to see what this does to the US economy. Doesnt seem my nephew has many job prospects at the moment